Carlos Fernández De Larrea

About me

Featured publications

• Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia

  Authors:

  Moreno DF; López-Guerra M; Paz S; Oliver-Caldés A; Mena MP;

  (...)

  Jiménez-Segura R; Bladé J; Rosiñol L; Colomer D; Fernández de Larrea C .

  See complete list of authors

  Reference: British Journal Of Haematology 2023.

• T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells

  Authors:

  Battram, Anthony M; Oliver-Caldes, Aina; Suarez-Lledo, Maria; Lozano, Miquel; Crespo, Miquel Bosch i;

  (...)

  Cid, Joan; Moreno, David F; Rodriguez-Lobato, Luis Gerardo; Urbano-Ispizua, Alvaro; de Larrea, Carlos Fernandez.

  See complete list of authors

  Reference: Molecular Therapy-Methods & Clinical Development 2022.

• Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

  Authors:

  De Larrea, CF; Kyle, R; Rosiñol, L; Paiva, B; Engelhardt, M;

  (...)

  Kaiser, M; San Miguel, J; Bladé, J; Rajkumar, SV; Mateos, MV.

  See complete list of authors

  Reference: Blood Cancer Journal 2021.

• Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease

  Authors:

  Isola, I; Brasó-Maristany, F; Moreno, DF; Mena, MP; Oliver-Calders, A;

  (...)

  Bladé, J; Rosiñol, L; Prat, A; Lozano, E; de Larrea, CF.

  See complete list of authors

  Reference: Frontiers In Immunology 2021.

• Treatment of Patients with Monoclonal Gammopathy of Clinical Significance

  Authors:

  Moreno, DF; Rosiñol, L; Cibeira, MT; Bladé, J; de Larrea, CF;

  Reference: Cancers 2021.

• Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy

  Authors:

  Moreno, DF; Pereira, A; Tovar, N; Cibeira, MT; Magnano, L;

  (...)

  Oliver-Caldés, A; Mena, MP; Rosiñol, L; Bladé, J; de Larrea, CF.

  See complete list of authors

  Reference: Cancers 2021.

• Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure

  Authors:

  Uribe-Herranz, Mireia; Klein-Gonzalez, Nela; Rodriguez-Lobato, Luis Gerardo; Juan, Manel; Fernandez de Larrea, Carlos;

  Reference: International Journal Of Molecular Sciences 2021.

• Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma

  Authors:

  Lozano E; Mena MP; Díaz T; Martin-Antonio B; León S;

  (...)

  Cibeira MT; Bladé J; Prat A; Rosiñol L; Fernández de Larrea C .

  See complete list of authors

  Reference: Clinical Cancer Research 2020.

• Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression

  Authors:

  Fernandez de Larrea, Carlos; Isola, Ignacio; Pereira, Arturo; Teresa Cibeira, Ma; Magnano, Laura;

  (...)

  Lozano, Ester; Rozman, Maria; Yague, Jordi; Blade, Joan; Rosinol, Laura;.

  See complete list of authors

  Reference: Leukemia 2018.

• Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.

  Authors:

  Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I;

  Rosiñol L; Bladé J; Fernández de Larrea C .

  Reference: Amyloid-Journal Of Protein Folding Disorders 2018.

Featured Projects

• Estrategias novedosas de ingeniería avanzada para optimizar la función y la persistencia de las células CAR-T en el mieloma múltiple

  Principal investigator: Carlos Fernández de Larrea Rodríguez

  Funder: Instituto de Salud Carlos III

  Code: PI22/00647

  Duration: 01/01/2023 - 31/12/2025

• Estrategias para superar las recaídas por escape antigénica y mejorar la persistencia de las células CART en el mieloma múltiple

  Principal investigator: Carlos Fernández de Larrea Rodríguez

  Funder: Asociación Española Contra el Cáncer (AECC)

  Code: LABAE21971FERN

  Duration: 01/11/2021 - 31/10/2024

• Optimización de la inmunoterapia con células T CAR a través de la inhibición de inmune checkpoints para alcanzar una respuesta prologada en pacientes con mieloma múltiple

  Principal investigator: Carlos Fernández de Larrea Rodríguez

  Funder: Instituto de Salud Carlos III

  Code: PI19/00669

  Duration: 01/01/2020 - 31/12/2022

• Ensayo clínico fase II sobre el uso de un CART humanizado dirigido contra BCMA (ARI0002h) en pacientes con mieloma múltiple recaído/refractario a inhibidores del proteasoma, inmunomoduladores y anticuerpos anti-CD38

  Principal investigator: Carlos Fernández de Larrea Rodríguez

  Funder: Instituto de Salud Carlos III

  Code: ICI19/00025

  Duration: 01/01/2020 - 31/12/2023

• Grupo de Investigación Consolidado (GRC) Unidad de Amiloidosis y Mieloma

  Principal investigator: Carlos Fernández de Larrea Rodríguez

  Funder: Generalitat de Catalunya

  Code: 2017 SGR 00792

  Duration: 01/01/2017 - 31/12/2020